Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk

['lizbeth]

Well bless my little pessimistic soul, I was just telling James that I didn't think there would be another vaccine trial anytime soon.

However, I think he has an angel on his shoulder because I just got the unofficial word of a second trial for after Herceptin is finished.

I copied and pasted the information from clinicaltrials.gov

Perhaps the phase III trial with the 50 slots is for post Herceptin vaccine trial. If I remember correctly the phase II has been finished already.


Several participants in the AE37/GP2 trial mentioned "that lady from San Diego". Thank you, Thank you, Thank you for participating with me.

If you even think that you might qualify, or not. Make the call for information on the vaccine trials.

Thanks again,

Elizabeth

[mscaruso]

'Lizbeth - forgive me - where did you post it? And is it enrolling right now or will be in the future? Thanks!

[MargaretAlice]

Spent part of last week at MD Anderson, eval by MO. Recommendation was the ATEMPT clinical trial.

I am very interested in immunotherapy. If I had qualified, I was there at the right time to put my name in the hat. The clinical nurse supporting the MO was also closely following the upcoming NeuVax trial. I think we chimed in together on the 4 positive node requirement, eliminated another patient from consideration. Mittendorf's research nurse suggested I watch for any info published about a different vaccine, "AE37".

[MargaretAlice]

http://www.mdanderson.org/patient-an...son/index.html

The NeuVax clinical trial will be led by Elizabeth Mittendorf.


2011-0595(clinicaltrials.gov NCT No: NCT01479244) Title:PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive
Breast Cancer with Low to Intermediate HER2 Expression with
NeuVax Treatment Principal Investigator:Elizabeth A. Mittendorf Treatment Agent:GM-CSF; NeuVax Study Status:Open Study Description:The goal of this part of the clinical research study is to learn more about the
amounts of the HER2 protein in patients who had breast cancer using the Bond
Oracle HER2 IHC System.